You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Medtronic
McKinsey
Boehringer Ingelheim
Express Scripts

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

FABRAZYME Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: FABRAZYME
Patents:21
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for FABRAZYME
Recent Clinical Trials for FABRAZYME

Identify potential brand extensions & biosimilar entrants

SponsorPhase
SanofiPhase 4
ActelionPhase 1
University of Alabama at BirminghamN/A

See all FABRAZYME clinical trials

Pharmacology for FABRAZYME
Ingredient-typealpha-Glucosidases

Company Disclosures: US Patents for FABRAZYME

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 001 2003-04-24   Start Trial Mount Sinai School of Medicine of the City of New York (New York, NY) 2039-02-26 RX Orphan company
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 002 2003-04-24   Start Trial Mount Sinai School of Medicine of the City of New York (New York, NY) 2039-02-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for FABRAZYME

These patents were identified by searching patent claims

Supplementary Protection Certificates for FABRAZYME

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2010/021 Ireland   Start Trial PRODUCT NAME: AGALSIDASE ALFA; NAT REGISTRATION NO/DATE: EU/1/01/188/001-003 20010803; FIRST REGISTRATION NO/DATE: EU/1/01/189/001 03/08/2001 EUROPEAN UNION EU/1/01/188/001-003 03/08/2001 EUROPEAN UNION EU/1/01/189/001 20010803
13C0064 France   Start Trial PRODUCT NAME: AGALSIDASE BETA; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010807
C300627 Netherlands   Start Trial PRODUCT NAME: METHOD FOR PRODUCING SECRETED PROTIENS; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010803
1390054-3 Sweden   Start Trial PRODUCT NAME: AGALSIDAS BETA; REG. NO/DATE: EU/1/01/188/001 20010803
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Mallinckrodt
Baxter
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.